Amersham International And Nycomed To Merge
UK company Amersham International, which has just announced that it ismerging its life sciences business with Pharmacia Biotech (Marketletters passim), is now merging with the Norwegian health care company Nycomed, which specializes in imaging agents and pharmaceuticals.
The new company will be called Nycomed Amersham and will have a leading position in in vivo diagnostic imaging agents, along with the number one position in research-based biotechnology supply that is a result of the formation of Amersham Pharmacia Biotech.
Amersham shareholders will own 47% of the new company's enlarged issued share capital, and Nycomed shareholders will be offered new shares representing 53%. Nycomed shareholders are also being offered a special dividend of 5.62 Norwegian kroner (76 cents) per Nycomed share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze